Objective :
Portfolio Management of the client’s Infectious Disease portfolio to ascertain the best course of action for the future clinical and commercial development of therapeutics under the said portfolio, leading to increased ROI
Problem Statement:
A small-Pharma client based in Israel involved DelveInsight to manage their portfolio of candidates indicated for various infectious diseases. The client provided DelveInsight with the task of assessing the best strategic direction for each asset through extensive market research analysis, for development for US and EU regions.
Our Methodology:
- Infectious Disease Market Assessment
- Opportunity Assessment for each candidate
- Unmet Need Analysis of Patients in regions of the client’s interest
- Market Valuation and Future Trend Overview
Results:
- Detailed landscaping of the arena in the regions of client’s interest
- Asset prioritization to segregate assets for development or divestiture
- Opportunity Assessment to allocate resources for future development
- Market Assessment to understand Future Market Share
Our Related Services
Portfolio Management
Matching Competencies and vision to develop a strong portfolio for future gains
Market Assessment
Achieve Breakthroughs with all-encompassing Market Outlook Research
Sample Visuals
Get Visuals
Get Visuals
Transform your business with our case study. Download now and achieve your goals!
Related Insights
In-Licensing Opportunity
A large client based in USA, involved in drug delivery devices, with effective marketing and commercialization presence across the globe, wanted to in-license potential dMTS based drug delivery asset...
View CaseOut-Licensing Opportunity
A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from acr...
View CaseGo-To-Market Strategy
A medium pharmaceutical client based in United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe...
View Case